Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT07648771
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Pain
  • Ketamine

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ketamine (Ketalar) — DRUG
    Intravenous ketamine infusion delivered as part of routine clinical care

Study Details

Ketamine is an anesthetic drug that is sometimes used to relieve chronic pain. The goal of this observational study is to learn about how patients respond to ketamine infusions for chronic pain. Note: This study does not provide ketamine - instead, this study uses surveys to follow patients who are already scheduled to receive ketamine infusions as part of their regular medical care. We will also follow a second group of patients who were recommended ketamine infusions by their doctor but were denied insurance coverage for this treatment. These participants will complete the same surveys for up to 16 weeks, starting from when their treatment was originally scheduled. Comparing this group to patients who received ketamine will help researchers better understand ketamine's effects and how insurance denials affect chronic pain patients.

Key Dates

Start date
Aug 31, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2034
Completion
Dec 31, 2034

Study Design

Enrollment
800 participants (estimated)

Arms

  • Arm: Ketamine Treated Cohort
    Observational cohort of patients who received ketamine infusion therapy for the treatment of chronic pain
  • Arm: Denied Treatment Cohort
    Observational cohort of patients who were recommended ketamine infusion therapy but did not receive this treatment due to lack of insurance coverage

Primary Outcome Measure

Change in PROMIS Pain Interference Score From Baseline [ Time Frame: From enrollment to 16 weeks after the ketamine infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford Health CareStanfordCalifornia94305
Protocol Director
[email protected]
650-264-9442

Find similar trials in Stanford, CA

By research site
Stanford Health Care· Stanford, CA

Related Studies